{"id":11889,"date":"2024-01-22T17:02:51","date_gmt":"2024-01-22T17:02:51","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=11889"},"modified":"2026-01-22T16:02:19","modified_gmt":"2026-01-22T14:02:19","slug":"22-janvier-2024-maat-pharma-bilan-semestriel-du-contrat-de-liquidite-contracte-avec-la-societe-de-bourse-kepler-cheuvreux","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/22-janvier-2024-maat-pharma-bilan-semestriel-du-contrat-de-liquidite-contracte-avec-la-societe-de-bourse-kepler-cheuvreux\/","title":{"rendered":"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux"},"content":{"rendered":"<h3 style=\"text-align: center;\"><span style=\"color: #283583;\">MaaT Pharma\u00a0: Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux <\/span><\/h3>\n<p><strong><span style=\"color: #283583;\">Lyon, France, 22 janvier 2024, 18h00 CET &#8211; <\/span><\/strong><a href=\"https:\/\/www.maatpharma.com\/fr\/\"><strong>MaaT\u00a0Pharma<\/strong><\/a> <strong><span style=\"color: #283583;\">(EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem Therapies<sup>TM<\/sup> (MET)<sup>1<\/sup> visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers,<\/span><\/strong>annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux.<\/p>\n<p>Au titre du contrat de liquidit\u00e9 confi\u00e9 par la Soci\u00e9t\u00e9 MaaT Pharma \u00e0 Kepler Cheuvreux, les moyens figurant au compte de liquidit\u00e9 au 31 d\u00e9cembre 2023 \u00e9taient :<\/p>\n<ul>\n<li>24 236 titres<\/li>\n<li>34 60 \u20ac en esp\u00e8ces<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 627<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 368<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 18 328 titres pour 122 49 \u20ac<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 576 titres pour 64 03 \u20ac<\/li>\n<\/ul>\n<p>Il est rappel\u00e9 :<\/p>\n<ul>\n<li>que lors du dernier bilan du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 :<\/li>\n<li>15 484 titres<\/li>\n<li>41 13 \u20ac en esp\u00e8ces<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552<\/li>\n<li>Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac<\/li>\n<li>Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li>que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 :<\/li>\n<li>0 titres<\/li>\n<li>200 00 \u20ac en esp\u00e8ces<\/li>\n<\/ul>\n<p>Le contrat de liquidit\u00e9 est mis en \u0153uvre depuis le 14 mars 2022, en vertu de l&rsquo;autorisation accord\u00e9e par l&rsquo;Assembl\u00e9e G\u00e9n\u00e9rale du 3 mars 2022, renouvel\u00e9e le 19 juin 2023. La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise.<\/p>\n<table width=\"609\">\n<tbody>\n<tr>\n<td width=\"74\"><\/td>\n<td colspan=\"3\" width=\"261\">Achats<\/td>\n<td width=\"13\"><\/td>\n<td colspan=\"3\" width=\"261\">Ventes<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>627<\/td>\n<td>18 328<\/td>\n<td>122 340,49<\/td>\n<td><\/td>\n<td>368<\/td>\n<td>9 576<\/td>\n<td>64 693,03<\/td>\n<\/tr>\n<tr>\n<td>03\/07\/2023<\/td>\n<td>5<\/td>\n<td>447<\/td>\n<td>3 111,12<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>04\/07\/2023<\/td>\n<td>21<\/td>\n<td>845<\/td>\n<td>5 391,10<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>05\/07\/2023<\/td>\n<td>4<\/td>\n<td>284<\/td>\n<td>1 848,84<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,90<\/td>\n<\/tr>\n<tr>\n<td>06\/07\/2023<\/td>\n<td>4<\/td>\n<td>111<\/td>\n<td>747,03<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,84<\/td>\n<\/tr>\n<tr>\n<td>07\/07\/2023<\/td>\n<td>3<\/td>\n<td>70<\/td>\n<td>466,20<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>10\/07\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>335,00<\/td>\n<\/tr>\n<tr>\n<td>12\/07\/2023<\/td>\n<td>1<\/td>\n<td>30<\/td>\n<td>201,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>13\/07\/2023<\/td>\n<td>3<\/td>\n<td>20<\/td>\n<td>133,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>14\/07\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,62<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,62<\/td>\n<\/tr>\n<tr>\n<td>17\/07\/2023<\/td>\n<td>3<\/td>\n<td>110<\/td>\n<td>715,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>18\/07\/2023<\/td>\n<td>3<\/td>\n<td>100<\/td>\n<td>640,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>19\/07\/2023<\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>128,00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>40<\/td>\n<td>258,40<\/td>\n<\/tr>\n<tr>\n<td>20\/07\/2023<\/td>\n<td>1<\/td>\n<td>40<\/td>\n<td>256,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>323,00<\/td>\n<\/tr>\n<tr>\n<td>21\/07\/2023<\/td>\n<td>1<\/td>\n<td>40<\/td>\n<td>256,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>24\/07\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>30<\/td>\n<td>192,60<\/td>\n<\/tr>\n<tr>\n<td>25\/07\/2023<\/td>\n<td>2<\/td>\n<td>21<\/td>\n<td>134,40<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,40<\/td>\n<\/tr>\n<tr>\n<td>26\/07\/2023<\/td>\n<td>2<\/td>\n<td>51<\/td>\n<td>325,38<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<\/tr>\n<tr>\n<td>27\/07\/2023<\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>320,00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>66<\/td>\n<td>423,72<\/td>\n<\/tr>\n<tr>\n<td>28\/07\/2023<\/td>\n<td>3<\/td>\n<td>100<\/td>\n<td>633,00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>54<\/td>\n<td>345,60<\/td>\n<\/tr>\n<tr>\n<td>31\/07\/2023<\/td>\n<td>3<\/td>\n<td>100<\/td>\n<td>621,00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>71<\/td>\n<td>454,40<\/td>\n<\/tr>\n<tr>\n<td>01\/08\/2023<\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>320,00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>129<\/td>\n<td>833,34<\/td>\n<\/tr>\n<tr>\n<td>02\/08\/2023<\/td>\n<td>2<\/td>\n<td>80<\/td>\n<td>508,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>03\/08\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>50<\/td>\n<td>320,00<\/td>\n<\/tr>\n<tr>\n<td>04\/08\/2023<\/td>\n<td>5<\/td>\n<td>31<\/td>\n<td>195,30<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,30<\/td>\n<\/tr>\n<tr>\n<td>07\/08\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>128,00<\/td>\n<\/tr>\n<tr>\n<td>08\/08\/2023<\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>128,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>09\/08\/2023<\/td>\n<td>2<\/td>\n<td>24<\/td>\n<td>152,16<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>10\/08\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<\/tr>\n<tr>\n<td>11\/08\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>7<\/td>\n<td>44,80<\/td>\n<\/tr>\n<tr>\n<td>14\/08\/2023<\/td>\n<td>4<\/td>\n<td>50<\/td>\n<td>315,00<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>15\/08\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,32<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>31<\/td>\n<td>198,40<\/td>\n<\/tr>\n<tr>\n<td>16\/08\/2023<\/td>\n<td>3<\/td>\n<td>31<\/td>\n<td>195,30<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<\/tr>\n<tr>\n<td>17\/08\/2023<\/td>\n<td>1<\/td>\n<td>10<\/td>\n<td>63,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>128,00<\/td>\n<\/tr>\n<tr>\n<td>18\/08\/2023<\/td>\n<td>2<\/td>\n<td>21<\/td>\n<td>132,30<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<\/tr>\n<tr>\n<td>21\/08\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>320,00<\/td>\n<\/tr>\n<tr>\n<td>22\/08\/2023<\/td>\n<td>2<\/td>\n<td>41<\/td>\n<td>258,30<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,38<\/td>\n<\/tr>\n<tr>\n<td>23\/08\/2023<\/td>\n<td>3<\/td>\n<td>30<\/td>\n<td>188,70<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>60<\/td>\n<td>382,20<\/td>\n<\/tr>\n<tr>\n<td>24\/08\/2023<\/td>\n<td>3<\/td>\n<td>30<\/td>\n<td>189,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>128,00<\/td>\n<\/tr>\n<tr>\n<td>25\/08\/2023<\/td>\n<td>6<\/td>\n<td>116<\/td>\n<td>709,92<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>94<\/td>\n<td>579,98<\/td>\n<\/tr>\n<tr>\n<td>28\/08\/2023<\/td>\n<td>5<\/td>\n<td>90<\/td>\n<td>547,20<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>11<\/td>\n<td>69,30<\/td>\n<\/tr>\n<tr>\n<td>29\/08\/2023<\/td>\n<td>4<\/td>\n<td>31<\/td>\n<td>192,20<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>48<\/td>\n<td>304,32<\/td>\n<\/tr>\n<tr>\n<td>30\/08\/2023<\/td>\n<td>6<\/td>\n<td>370<\/td>\n<td>2 353,20<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>31\/08\/2023<\/td>\n<td>5<\/td>\n<td>109<\/td>\n<td>683,43<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>05\/09\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,30<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,30<\/td>\n<\/tr>\n<tr>\n<td>06\/09\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,32<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,32<\/td>\n<\/tr>\n<tr>\n<td>07\/09\/2023<\/td>\n<td>7<\/td>\n<td>248<\/td>\n<td>1 550,00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>150<\/td>\n<td>969,00<\/td>\n<\/tr>\n<tr>\n<td>08\/09\/2023<\/td>\n<td>5<\/td>\n<td>244<\/td>\n<td>1 520,12<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>151<\/td>\n<td>966,40<\/td>\n<\/tr>\n<tr>\n<td>11\/09\/2023<\/td>\n<td>2<\/td>\n<td>6<\/td>\n<td>38,04<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>12\/09\/2023<\/td>\n<td>7<\/td>\n<td>344<\/td>\n<td>2 132,80<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>100<\/td>\n<td>626,00<\/td>\n<\/tr>\n<tr>\n<td>13\/09\/2023<\/td>\n<td>2<\/td>\n<td>31<\/td>\n<td>195,30<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>81<\/td>\n<td>515,16<\/td>\n<\/tr>\n<tr>\n<td>14\/09\/2023<\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>126,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>128,00<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">Achats<\/td>\n<td><\/td>\n<td colspan=\"3\">Ventes<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>627<\/td>\n<td>18 328<\/td>\n<td>122 340,49<\/td>\n<td><\/td>\n<td>368<\/td>\n<td>9 576<\/td>\n<td>64 693,03<\/td>\n<\/tr>\n<tr>\n<td>18\/09\/2023<\/td>\n<td>4<\/td>\n<td>151<\/td>\n<td>943,75<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>80<\/td>\n<td>500,80<\/td>\n<\/tr>\n<tr>\n<td>19\/09\/2023<\/td>\n<td>5<\/td>\n<td>60<\/td>\n<td>369,00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>21<\/td>\n<td>130,20<\/td>\n<\/tr>\n<tr>\n<td>20\/09\/2023<\/td>\n<td>2<\/td>\n<td>10<\/td>\n<td>63,00<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>80<\/td>\n<td>511,20<\/td>\n<\/tr>\n<tr>\n<td>21\/09\/2023<\/td>\n<td>4<\/td>\n<td>100<\/td>\n<td>618,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>50<\/td>\n<td>315,00<\/td>\n<\/tr>\n<tr>\n<td>22\/09\/2023<\/td>\n<td>7<\/td>\n<td>239<\/td>\n<td>1 465,07<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,28<\/td>\n<\/tr>\n<tr>\n<td>25\/09\/2023<\/td>\n<td>4<\/td>\n<td>110<\/td>\n<td>684,20<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>313,00<\/td>\n<\/tr>\n<tr>\n<td>26\/09\/2023<\/td>\n<td>9<\/td>\n<td>430<\/td>\n<td>2 558,50<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>314,50<\/td>\n<\/tr>\n<tr>\n<td>27\/09\/2023<\/td>\n<td>12<\/td>\n<td>791<\/td>\n<td>4 445,42<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>122<\/td>\n<td>744,20<\/td>\n<\/tr>\n<tr>\n<td>28\/09\/2023<\/td>\n<td>12<\/td>\n<td>710<\/td>\n<td>3 564,20<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>200<\/td>\n<td>1 008,00<\/td>\n<\/tr>\n<tr>\n<td>29\/09\/2023<\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>252,00<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>300<\/td>\n<td>1 554,00<\/td>\n<\/tr>\n<tr>\n<td>02\/10\/2023<\/td>\n<td>3<\/td>\n<td>130<\/td>\n<td>661,70<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>03\/10\/2023<\/td>\n<td>18<\/td>\n<td>540<\/td>\n<td>2 624,40<\/td>\n<td><\/td>\n<td>11<\/td>\n<td>400<\/td>\n<td>2 000,00<\/td>\n<\/tr>\n<tr>\n<td>04\/10\/2023<\/td>\n<td>3<\/td>\n<td>130<\/td>\n<td>666,90<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>110<\/td>\n<td>569,80<\/td>\n<\/tr>\n<tr>\n<td>05\/10\/2023<\/td>\n<td>3<\/td>\n<td>234<\/td>\n<td>1 404,00<\/td>\n<td><\/td>\n<td>18<\/td>\n<td>588<\/td>\n<td>3 580,92<\/td>\n<\/tr>\n<tr>\n<td>06\/10\/2023<\/td>\n<td>2<\/td>\n<td>50<\/td>\n<td>313,00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>60<\/td>\n<td>379,80<\/td>\n<\/tr>\n<tr>\n<td>09\/10\/2023<\/td>\n<td>9<\/td>\n<td>190<\/td>\n<td>1 155,20<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>10\/10\/2023<\/td>\n<td>5<\/td>\n<td>105<\/td>\n<td>628,95<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>30<\/td>\n<td>183,00<\/td>\n<\/tr>\n<tr>\n<td>11\/10\/2023<\/td>\n<td>9<\/td>\n<td>167<\/td>\n<td>993,65<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>49<\/td>\n<td>300,37<\/td>\n<\/tr>\n<tr>\n<td>12\/10\/2023<\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>5,82<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>51<\/td>\n<td>306,00<\/td>\n<\/tr>\n<tr>\n<td>13\/10\/2023<\/td>\n<td>6<\/td>\n<td>73<\/td>\n<td>427,78<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>23<\/td>\n<td>140,30<\/td>\n<\/tr>\n<tr>\n<td>16\/10\/2023<\/td>\n<td>1<\/td>\n<td>99<\/td>\n<td>588,06<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>48<\/td>\n<td>288,00<\/td>\n<\/tr>\n<tr>\n<td>17\/10\/2023<\/td>\n<td>2<\/td>\n<td>11<\/td>\n<td>66,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>5,98<\/td>\n<\/tr>\n<tr>\n<td>18\/10\/2023<\/td>\n<td>3<\/td>\n<td>35<\/td>\n<td>211,75<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>39<\/td>\n<td>239,85<\/td>\n<\/tr>\n<tr>\n<td>19\/10\/2023<\/td>\n<td>6<\/td>\n<td>139<\/td>\n<td>849,29<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>80<\/td>\n<td>498,40<\/td>\n<\/tr>\n<tr>\n<td>20\/10\/2023<\/td>\n<td>3<\/td>\n<td>8<\/td>\n<td>48,72<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>21<\/td>\n<td>129,99<\/td>\n<\/tr>\n<tr>\n<td>23\/10\/2023<\/td>\n<td>4<\/td>\n<td>67<\/td>\n<td>414,73<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>124,00<\/td>\n<\/tr>\n<tr>\n<td>24\/10\/2023<\/td>\n<td>5<\/td>\n<td>74<\/td>\n<td>454,36<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>21<\/td>\n<td>130,20<\/td>\n<\/tr>\n<tr>\n<td>25\/10\/2023<\/td>\n<td>2<\/td>\n<td>18<\/td>\n<td>111,60<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,22<\/td>\n<\/tr>\n<tr>\n<td>26\/10\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>8<\/td>\n<td>339<\/td>\n<td>2 278,08<\/td>\n<\/tr>\n<tr>\n<td>27\/10\/2023<\/td>\n<td>5<\/td>\n<td>140<\/td>\n<td>974,40<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>49<\/td>\n<td>348,88<\/td>\n<\/tr>\n<tr>\n<td>30\/10\/2023<\/td>\n<td>6<\/td>\n<td>90<\/td>\n<td>632,70<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>21<\/td>\n<td>151,20<\/td>\n<\/tr>\n<tr>\n<td>31\/10\/2023<\/td>\n<td>2<\/td>\n<td>40<\/td>\n<td>286,40<\/td>\n<td><\/td>\n<td>12<\/td>\n<td>354<\/td>\n<td>2 708,10<\/td>\n<\/tr>\n<tr>\n<td>01\/11\/2023<\/td>\n<td>4<\/td>\n<td>400<\/td>\n<td>3 164,00<\/td>\n<td><\/td>\n<td>10<\/td>\n<td>338<\/td>\n<td>2 879,76<\/td>\n<\/tr>\n<tr>\n<td>02\/11\/2023<\/td>\n<td>19<\/td>\n<td>1 720<\/td>\n<td>13 553,60<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>03\/11\/2023<\/td>\n<td>22<\/td>\n<td>1 108<\/td>\n<td>8 110,56<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>06\/11\/2023<\/td>\n<td>5<\/td>\n<td>77<\/td>\n<td>599,83<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>82<\/td>\n<td>655,18<\/td>\n<\/tr>\n<tr>\n<td>07\/11\/2023<\/td>\n<td>5<\/td>\n<td>95<\/td>\n<td>787,55<\/td>\n<td><\/td>\n<td>8<\/td>\n<td>140<\/td>\n<td>1 164,80<\/td>\n<\/tr>\n<tr>\n<td>08\/11\/2023<\/td>\n<td>7<\/td>\n<td>125<\/td>\n<td>1 028,75<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>20<\/td>\n<td>166,00<\/td>\n<\/tr>\n<tr>\n<td>09\/11\/2023<\/td>\n<td>10<\/td>\n<td>207<\/td>\n<td>1 674,63<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>6<\/td>\n<td>49,80<\/td>\n<\/tr>\n<tr>\n<td>10\/11\/2023<\/td>\n<td>20<\/td>\n<td>216<\/td>\n<td>1 736,64<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>8,06<\/td>\n<\/tr>\n<tr>\n<td>13\/11\/2023<\/td>\n<td>11<\/td>\n<td>117<\/td>\n<td>932,49<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>14\/11\/2023<\/td>\n<td>4<\/td>\n<td>69<\/td>\n<td>539,58<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>48<\/td>\n<td>379,68<\/td>\n<\/tr>\n<tr>\n<td>15\/11\/2023<\/td>\n<td>11<\/td>\n<td>270<\/td>\n<td>2 060,10<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>140<\/td>\n<td>1 104,60<\/td>\n<\/tr>\n<tr>\n<td>16\/11\/2023<\/td>\n<td>5<\/td>\n<td>121<\/td>\n<td>917,18<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>75<\/td>\n<td>574,50<\/td>\n<\/tr>\n<tr>\n<td>17\/11\/2023<\/td>\n<td>3<\/td>\n<td>90<\/td>\n<td>695,70<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>20\/11\/2023<\/td>\n<td>10<\/td>\n<td>484<\/td>\n<td>3 562,24<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>61<\/td>\n<td>461,16<\/td>\n<\/tr>\n<tr>\n<td>21\/11\/2023<\/td>\n<td>13<\/td>\n<td>303<\/td>\n<td>2 172,51<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>92<\/td>\n<td>678,96<\/td>\n<\/tr>\n<tr>\n<td>22\/11\/2023<\/td>\n<td>4<\/td>\n<td>63<\/td>\n<td>451,71<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>43<\/td>\n<td>313,90<\/td>\n<\/tr>\n<tr>\n<td>23\/11\/2023<\/td>\n<td>4<\/td>\n<td>93<\/td>\n<td>675,18<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>24\/11\/2023<\/td>\n<td>4<\/td>\n<td>65<\/td>\n<td>467,35<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>27\/11\/2023<\/td>\n<td>8<\/td>\n<td>161<\/td>\n<td>1 122,17<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>7,14<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td colspan=\"3\">Achats<\/td>\n<td><\/td>\n<td colspan=\"3\">Ventes<\/td>\n<\/tr>\n<tr>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<td><\/td>\n<td width=\"74\">Nombre de<br \/>\ntransactions<\/td>\n<td width=\"74\">Nombre de<br \/>\ntitres<\/td>\n<td width=\"113\">Capitaux en EUR<\/td>\n<\/tr>\n<tr>\n<td>Total<\/td>\n<td>627<\/td>\n<td>18 328<\/td>\n<td>122 340,49<\/td>\n<td><\/td>\n<td>368<\/td>\n<td>9 576<\/td>\n<td>64 693,03<\/td>\n<\/tr>\n<tr>\n<td>28\/11\/2023<\/td>\n<td>6<\/td>\n<td>140<\/td>\n<td>952,00<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>110<\/td>\n<td>767,80<\/td>\n<\/tr>\n<tr>\n<td>29\/11\/2023<\/td>\n<td>3<\/td>\n<td>200<\/td>\n<td>1 380,00<\/td>\n<td><\/td>\n<td>1<\/td>\n<td>1<\/td>\n<td>6,96<\/td>\n<\/tr>\n<tr>\n<td>30\/11\/2023<\/td>\n<td>5<\/td>\n<td>140<\/td>\n<td>945,00<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>90<\/td>\n<td>610,20<\/td>\n<\/tr>\n<tr>\n<td>01\/12\/2023<\/td>\n<td>21<\/td>\n<td>389<\/td>\n<td>2 594,63<\/td>\n<td><\/td>\n<td>13<\/td>\n<td>415<\/td>\n<td>3 037,80<\/td>\n<\/tr>\n<tr>\n<td>04\/12\/2023<\/td>\n<td>2<\/td>\n<td>100<\/td>\n<td>685,00<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>147<\/td>\n<td>1 043,70<\/td>\n<\/tr>\n<tr>\n<td>05\/12\/2023<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>65<\/td>\n<td>455,00<\/td>\n<\/tr>\n<tr>\n<td>06\/12\/2023<\/td>\n<td>1<\/td>\n<td>17<\/td>\n<td>118,32<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>75<\/td>\n<td>525,00<\/td>\n<\/tr>\n<tr>\n<td>07\/12\/2023<\/td>\n<td>11<\/td>\n<td>349<\/td>\n<td>2 348,77<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>90<\/td>\n<td>618,30<\/td>\n<\/tr>\n<tr>\n<td>08\/12\/2023<\/td>\n<td>15<\/td>\n<td>251<\/td>\n<td>1 641,54<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>61<\/td>\n<td>405,65<\/td>\n<\/tr>\n<tr>\n<td>11\/12\/2023<\/td>\n<td>7<\/td>\n<td>154<\/td>\n<td>1 057,98<\/td>\n<td><\/td>\n<td>22<\/td>\n<td>1 083<\/td>\n<td>7 873,41<\/td>\n<\/tr>\n<tr>\n<td>12\/12\/2023<\/td>\n<td>4<\/td>\n<td>48<\/td>\n<td>340,80<\/td>\n<td><\/td>\n<td>9<\/td>\n<td>300<\/td>\n<td>2 145,00<\/td>\n<\/tr>\n<tr>\n<td>13\/12\/2023<\/td>\n<td>13<\/td>\n<td>238<\/td>\n<td>1 635,06<\/td>\n<td><\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>14\/12\/2023<\/td>\n<td>4<\/td>\n<td>60<\/td>\n<td>403,20<\/td>\n<td><\/td>\n<td>3<\/td>\n<td>60<\/td>\n<td>409,80<\/td>\n<\/tr>\n<tr>\n<td>15\/12\/2023<\/td>\n<td>9<\/td>\n<td>190<\/td>\n<td>1 271,10<\/td>\n<td><\/td>\n<td>11<\/td>\n<td>300<\/td>\n<td>2 055,00<\/td>\n<\/tr>\n<tr>\n<td>18\/12\/2023<\/td>\n<td>4<\/td>\n<td>20<\/td>\n<td>135,60<\/td>\n<td><\/td>\n<td>2<\/td>\n<td>15<\/td>\n<td>102,30<\/td>\n<\/tr>\n<tr>\n<td>19\/12\/2023<\/td>\n<td>5<\/td>\n<td>71<\/td>\n<td>484,22<\/td>\n<td><\/td>\n<td>5<\/td>\n<td>21<\/td>\n<td>143,43<\/td>\n<\/tr>\n<tr>\n<td>20\/12\/2023<\/td>\n<td>5<\/td>\n<td>60<\/td>\n<td>418,20<\/td>\n<td><\/td>\n<td>10<\/td>\n<td>225<\/td>\n<td>1 579,50<\/td>\n<\/tr>\n<tr>\n<td>21\/12\/2023<\/td>\n<td>10<\/td>\n<td>92<\/td>\n<td>623,76<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>81<\/td>\n<td>568,62<\/td>\n<\/tr>\n<tr>\n<td>22\/12\/2023<\/td>\n<td>10<\/td>\n<td>137<\/td>\n<td>946,67<\/td>\n<td><\/td>\n<td>15<\/td>\n<td>261<\/td>\n<td>1 827,00<\/td>\n<\/tr>\n<tr>\n<td>27\/12\/2023<\/td>\n<td>4<\/td>\n<td>75<\/td>\n<td>536,25<\/td>\n<td><\/td>\n<td>8<\/td>\n<td>210<\/td>\n<td>1 507,80<\/td>\n<\/tr>\n<tr>\n<td>28\/12\/2023<\/td>\n<td>3<\/td>\n<td>35<\/td>\n<td>250,25<\/td>\n<td><\/td>\n<td>4<\/td>\n<td>80<\/td>\n<td>583,20<\/td>\n<\/tr>\n<tr>\n<td>29\/12\/2023<\/td>\n<td>11<\/td>\n<td>314<\/td>\n<td>2 179,16<\/td>\n<td><\/td>\n<td>8<\/td>\n<td>165<\/td>\n<td>1 166,55<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h6><a href=\"#_ftnref1\" name=\"_ftn1\"><em><sup>[1]<\/sup><\/em><\/a> <em>Microbiome Ecosystem Therapy<sup>TM<\/sup> : Microbioth\u00e9rapie \u00e0 Ecosyst\u00e8me Complet<\/em><a href=\"#_ftnref1\" name=\"_ftn1\"><\/a><\/h6>\n<p><span style=\"color: #283583;\"><strong>A propos de MaaT Pharma<\/strong><\/span><\/p>\n<p>MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologies au stade clinique qui a mis au point une approche compl\u00e8te pour restaurer la symbiose microbiote\/h\u00f4te des patients atteints de cancers. Engag\u00e9e dans le traitement des cancers et de la maladie du greffon contre l\u2019h\u00f4te (GvH), une complication grave survenant apr\u00e8s une greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques, MaaT Pharma a lanc\u00e9 en mars 2022 en Europe un essai clinique de Phase 3 chez des patients atteints de GvH aigu\u00eb, apr\u00e8s avoir r\u00e9alis\u00e9 la preuve de concept de son approche dans un essai clinique de Phase 2. Sa puissante plateforme de d\u00e9couverte et d\u2019analyse, gutPrint\u00ae soutient le d\u00e9veloppement de son portefeuille de produits et son extension \u00e0 des indications plus larges, en aidant \u00e0 d\u00e9terminer de nouvelles cibles th\u00e9rapeutiques, \u00e0 \u00e9valuer les m\u00e9dicaments candidats et \u00e0 identifier des biomarqueurs pour la prise en charge de pathologies impliquant le microbiote. Les <em>Microbiome Ecosystem Therapies<sup>TM <\/sup><\/em>(Microbioth\u00e9rapies \u00e0 \u00e9cosyst\u00e8me complet) sont toutes produites dans le cadre tr\u00e8s standardis\u00e9 d\u2019une fabrication et de contr\u00f4les qualit\u00e9 cGMP, afin de garantir en toute s\u00e9curit\u00e9 l\u2019acc\u00e8s \u00e0 la diversit\u00e9 et \u00e0 la richesse du microbiote, sous forme orale ou d\u2019<em>enema<\/em>. MaaT Pharma b\u00e9n\u00e9ficie de l\u2019engagement de scientifiques de renomm\u00e9e mondiale et de relations \u00e9tablies avec les instances r\u00e9glementaires pour faire progresser l\u2019int\u00e9gration des th\u00e9rapies \u00e0 base de microbiote dans la pratique clinique.<\/p>\n<p>MaaT Pharma est la premi\u00e8re soci\u00e9t\u00e9 d\u00e9veloppant des m\u00e9dicaments \u00e0 base de microbiote cot\u00e9e sur Euronext Paris (Code mn\u00e9monique : MAAT).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MaaT Pharma\u00a0: Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux Lyon, France, 22 janvier 2024, 18h00 CET &#8211; MaaT\u00a0Pharma (EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM (MET)1 visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers,annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux. Au titre du contrat de liquidit\u00e9 confi\u00e9 par la Soci\u00e9t\u00e9 MaaT Pharma \u00e0 Kepler Cheuvreux, les moyens figurant au compte de liquidit\u00e9 au 31 d\u00e9cembre 2023 \u00e9taient : 24 236 titres 34 60 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 627 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 368 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 18 328 titres pour 122 49 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 576 titres pour 64 03 \u20ac Il est rappel\u00e9 : que lors du dernier bilan du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 : 15 484 titres 41 13 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac &nbsp; que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 : 0 titres 200 00 \u20ac en esp\u00e8ces Le contrat de liquidit\u00e9 est mis en \u0153uvre depuis le 14 mars 2022, en vertu de l&rsquo;autorisation accord\u00e9e par l&rsquo;Assembl\u00e9e G\u00e9n\u00e9rale du 3 mars 2022, renouvel\u00e9e le 19 juin 2023. La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise. Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 627 18 328 122 340,49 368 9 576 64 693,03 03\/07\/2023 5 447 3 111,12 &#8211; &#8211; &#8211; 04\/07\/2023 21 845 5 391,10 &#8211; &#8211; &#8211; 05\/07\/2023 4 284 1 848,84 1 1 6,90 06\/07\/2023 4 111 747,03 1 1 6,84 07\/07\/2023 3 70 466,20 &#8211; &#8211; &#8211; 10\/07\/2023 &#8211; &#8211; &#8211; 1 50 335,00 12\/07\/2023 1 30 201,00 &#8211; &#8211; &#8211; 13\/07\/2023 3 20 133,00 &#8211; &#8211; &#8211; 14\/07\/2023 1 1 6,62 1 1 6,62 17\/07\/2023 3 110 715,00 &#8211; &#8211; &#8211; 18\/07\/2023 3 100 640,00 &#8211; &#8211; &#8211; 19\/07\/2023 1 20 128,00 2 40 258,40 20\/07\/2023 1 40 256,00 1 50 323,00 21\/07\/2023 1 40 256,00 &#8211; &#8211; &#8211; 24\/07\/2023 &#8211; &#8211; &#8211; 1 30 192,60 25\/07\/2023 2 21 134,40 1 1 6,40 26\/07\/2023 2 51 325,38 1 1 6,38 27\/07\/2023 1 50 320,00 4 66 423,72 28\/07\/2023 3 100 633,00 2 54 345,60 31\/07\/2023 3 100 621,00 3 71 454,40 01\/08\/2023 1 50 320,00 4 129 833,34 02\/08\/2023 2 80 508,00 &#8211; &#8211; &#8211; 03\/08\/2023 &#8211; &#8211; &#8211; 3 50 320,00 04\/08\/2023 5 31 195,30 1 1 6,30 07\/08\/2023 &#8211; &#8211; &#8211; 1 20 128,00 08\/08\/2023 1 20 128,00 &#8211; &#8211; &#8211; 09\/08\/2023 2 24 152,16 &#8211; &#8211; &#8211; 10\/08\/2023 1 1 6,38 1 1 6,38 11\/08\/2023 1 1 6,38 2 7 44,80 14\/08\/2023 4 50 315,00 &#8211; &#8211; &#8211; 15\/08\/2023 1 1 6,32 2 31 198,40 16\/08\/2023 3 31 195,30 1 1 6,38 17\/08\/2023 1 10 63,00 1 20 128,00 18\/08\/2023 2 21 132,30 1 1 6,38 21\/08\/2023 &#8211; &#8211; &#8211; 2 50 320,00 22\/08\/2023 2 41 258,30 1 1 6,38 23\/08\/2023 3 30 188,70 2 60 382,20 24\/08\/2023 3 30 189,00 1 20 128,00 25\/08\/2023 6 116 709,92 5 94 579,98 28\/08\/2023 5 90 547,20 2 11 69,30 29\/08\/2023 4 31 192,20 3 48 304,32 30\/08\/2023 6 370 2 353,20 &#8211; &#8211; &#8211; 31\/08\/2023 5 109 683,43 &#8211; &#8211; &#8211; 05\/09\/2023 1 1 6,30 1 1 6,30 06\/09\/2023 1 1 6,32 1 1 6,32 07\/09\/2023 7 248 1 550,00 3 150 969,00 08\/09\/2023 5 244 1 520,12 2 151 966,40 11\/09\/2023 2 6 38,04 &#8211; &#8211; &#8211; 12\/09\/2023 7 344 2 132,80 4 100 626,00 13\/09\/2023 2 31 195,30 5 81 515,16 14\/09\/2023 1 20 126,00 1 20 128,00 Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 627 18 328 122 340,49 368 9 576 64 693,03 18\/09\/2023 4 151 943,75 3 80 500,80 19\/09\/2023 5 60 369,00 2 21 130,20 20\/09\/2023 2 10 63,00 4 80 511,20 21\/09\/2023 4 100 618,00 1 50 315,00 22\/09\/2023 7 239 1 465,07 1 1 6,28 25\/09\/2023 4 110 684,20 2 50 313,00 26\/09\/2023 9 430 2 558,50 2 50 314,50 27\/09\/2023 12 791 4 445,42 5 122 744,20 28\/09\/2023 12 710 3 564,20 2 200 1 008,00 29\/09\/2023 2 50 252,00 5 300 1 554,00 02\/10\/2023 3 130 661,70 &#8211; &#8211; &#8211; 03\/10\/2023 18 540 2 624,40 11 400 2 000,00 04\/10\/2023 3 130 666,90 3 110 569,80 05\/10\/2023 3 234 1 404,00 18 588 3 580,92 06\/10\/2023 2 50 313,00 3 60 379,80 09\/10\/2023 9 190 1 155,20 &#8211; &#8211; &#8211; 10\/10\/2023 5 105 628,95 2 30 183,00 11\/10\/2023 9 167 993,65 3 49 300,37 12\/10\/2023 1 1 5,82 4 51 306,00 13\/10\/2023 6 73 427,78 2 23 140,30 16\/10\/2023 1 99 588,06 1 48 288,00 17\/10\/2023 2 11 66,00 1 1 5,98 18\/10\/2023 3 35 211,75 3 39 239,85 19\/10\/2023 6 139 849,29 3 80 498,40 20\/10\/2023 3 8 48,72 2 21 129,99 23\/10\/2023 4 67 414,73 1 20 124,00 24\/10\/2023 5 74 454,36 2 21 130,20 25\/10\/2023 2 18 111,60 1 1 6,22 26\/10\/2023 &#8211; &#8211; &#8211; 8 339 2 278,08 27\/10\/2023 5 140 974,40 4 49 348,88 30\/10\/2023 6 90 632,70 1 21 151,20 31\/10\/2023 2<\/p>\n","protected":false},"author":2,"featured_media":7120,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[68],"year_press":[70],"class_list":["post-11889","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","category_press-financial-fr","year_press-2024-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"MaaT Pharma\u00a0: Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux Lyon, France, 22 janvier 2024, 18h00 CET &#8211; MaaT\u00a0Pharma (EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM (MET)1 visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers,annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux. Au titre du contrat de liquidit\u00e9 confi\u00e9 par la Soci\u00e9t\u00e9 MaaT Pharma \u00e0 Kepler Cheuvreux, les moyens figurant au compte de liquidit\u00e9 au 31 d\u00e9cembre 2023 \u00e9taient : 24 236 titres 34 60 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 627 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 368 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 18 328 titres pour 122 49 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 576 titres pour 64 03 \u20ac Il est rappel\u00e9 : que lors du dernier bilan du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 : 15 484 titres 41 13 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac &nbsp; que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 : 0 titres 200 00 \u20ac en esp\u00e8ces Le contrat de liquidit\u00e9 est mis en \u0153uvre depuis le 14 mars 2022, en vertu de l&rsquo;autorisation accord\u00e9e par l&rsquo;Assembl\u00e9e G\u00e9n\u00e9rale du 3 mars 2022, renouvel\u00e9e le 19 juin 2023. La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise. Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 627 18 328 122 340,49 368 9 576 64 693,03 03\/07\/2023 5 447 3 111,12 &#8211; &#8211; &#8211; 04\/07\/2023 21 845 5 391,10 &#8211; &#8211; &#8211; 05\/07\/2023 4 284 1 848,84 1 1 6,90 06\/07\/2023 4 111 747,03 1 1 6,84 07\/07\/2023 3 70 466,20 &#8211; &#8211; &#8211; 10\/07\/2023 &#8211; &#8211; &#8211; 1 50 335,00 12\/07\/2023 1 30 201,00 &#8211; &#8211; &#8211; 13\/07\/2023 3 20 133,00 &#8211; &#8211; &#8211; 14\/07\/2023 1 1 6,62 1 1 6,62 17\/07\/2023 3 110 715,00 &#8211; &#8211; &#8211; 18\/07\/2023 3 100 640,00 &#8211; &#8211; &#8211; 19\/07\/2023 1 20 128,00 2 40 258,40 20\/07\/2023 1 40 256,00 1 50 323,00 21\/07\/2023 1 40 256,00 &#8211; &#8211; &#8211; 24\/07\/2023 &#8211; &#8211; &#8211; 1 30 192,60 25\/07\/2023 2 21 134,40 1 1 6,40 26\/07\/2023 2 51 325,38 1 1 6,38 27\/07\/2023 1 50 320,00 4 66 423,72 28\/07\/2023 3 100 633,00 2 54 345,60 31\/07\/2023 3 100 621,00 3 71 454,40 01\/08\/2023 1 50 320,00 4 129 833,34 02\/08\/2023 2 80 508,00 &#8211; &#8211; &#8211; 03\/08\/2023 &#8211; &#8211; &#8211; 3 50 320,00 04\/08\/2023 5 31 195,30 1 1 6,30 07\/08\/2023 &#8211; &#8211; &#8211; 1 20 128,00 08\/08\/2023 1 20 128,00 &#8211; &#8211; &#8211; 09\/08\/2023 2 24 152,16 &#8211; &#8211; &#8211; 10\/08\/2023 1 1 6,38 1 1 6,38 11\/08\/2023 1 1 6,38 2 7 44,80 14\/08\/2023 4 50 315,00 &#8211; &#8211; &#8211; 15\/08\/2023 1 1 6,32 2 31 198,40 16\/08\/2023 3 31 195,30 1 1 6,38 17\/08\/2023 1 10 63,00 1 20 128,00 18\/08\/2023 2 21 132,30 1 1 6,38 21\/08\/2023 &#8211; &#8211; &#8211; 2 50 320,00 22\/08\/2023 2 41 258,30 1 1 6,38 23\/08\/2023 3 30 188,70 2 60 382,20 24\/08\/2023 3 30 189,00 1 20 128,00 25\/08\/2023 6 116 709,92 5 94 579,98 28\/08\/2023 5 90 547,20 2 11 69,30 29\/08\/2023 4 31 192,20 3 48 304,32 30\/08\/2023 6 370 2 353,20 &#8211; &#8211; &#8211; 31\/08\/2023 5 109 683,43 &#8211; &#8211; &#8211; 05\/09\/2023 1 1 6,30 1 1 6,30 06\/09\/2023 1 1 6,32 1 1 6,32 07\/09\/2023 7 248 1 550,00 3 150 969,00 08\/09\/2023 5 244 1 520,12 2 151 966,40 11\/09\/2023 2 6 38,04 &#8211; &#8211; &#8211; 12\/09\/2023 7 344 2 132,80 4 100 626,00 13\/09\/2023 2 31 195,30 5 81 515,16 14\/09\/2023 1 20 126,00 1 20 128,00 Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 627 18 328 122 340,49 368 9 576 64 693,03 18\/09\/2023 4 151 943,75 3 80 500,80 19\/09\/2023 5 60 369,00 2 21 130,20 20\/09\/2023 2 10 63,00 4 80 511,20 21\/09\/2023 4 100 618,00 1 50 315,00 22\/09\/2023 7 239 1 465,07 1 1 6,28 25\/09\/2023 4 110 684,20 2 50 313,00 26\/09\/2023 9 430 2 558,50 2 50 314,50 27\/09\/2023 12 791 4 445,42 5 122 744,20 28\/09\/2023 12 710 3 564,20 2 200 1 008,00 29\/09\/2023 2 50 252,00 5 300 1 554,00 02\/10\/2023 3 130 661,70 &#8211; &#8211; &#8211; 03\/10\/2023 18 540 2 624,40 11 400 2 000,00 04\/10\/2023 3 130 666,90 3 110 569,80 05\/10\/2023 3 234 1 404,00 18 588 3 580,92 06\/10\/2023 2 50 313,00 3 60 379,80 09\/10\/2023 9 190 1 155,20 &#8211; &#8211; &#8211; 10\/10\/2023 5 105 628,95 2 30 183,00 11\/10\/2023 9 167 993,65 3 49 300,37 12\/10\/2023 1 1 5,82 4 51 306,00 13\/10\/2023 6 73 427,78 2 23 140,30 16\/10\/2023 1 99 588,06 1 48 288,00 17\/10\/2023 2 11 66,00 1 1 5,98 18\/10\/2023 3 35 211,75 3 39 239,85 19\/10\/2023 6 139 849,29 3 80 498,40 20\/10\/2023 3 8 48,72 2 21 129,99 23\/10\/2023 4 67 414,73 1 20 124,00 24\/10\/2023 5 74 454,36 2 21 130,20 25\/10\/2023 2 18 111,60 1 1 6,22 26\/10\/2023 &#8211; &#8211; &#8211; 8 339 2 278,08 27\/10\/2023 5 140 974,40 4 49 348,88 30\/10\/2023 6 90 632,70 1 21 151,20 31\/10\/2023 2\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-22T17:02:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T14:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2362\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\",\"datePublished\":\"2024-01-22T17:02:51+00:00\",\"dateModified\":\"2026-01-22T14:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"},\"wordCount\":762,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\",\"name\":\"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"datePublished\":\"2024-01-22T17:02:51+00:00\",\"dateModified\":\"2026-01-22T14:02:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/12\\\/Website_maat_logo.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","og_locale":"fr_FR","og_type":"article","og_title":"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma","og_description":"MaaT Pharma\u00a0: Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux Lyon, France, 22 janvier 2024, 18h00 CET &#8211; MaaT\u00a0Pharma (EURONEXT : MAAT &#8211; la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 de biotechnologies en stade clinique avanc\u00e9, leader dans le d\u00e9veloppement de Microbiome Ecosystem TherapiesTM (MET)1 visant \u00e0 am\u00e9liorer la survie des patients atteints de cancers,annonce aujourd\u2019hui le bilan semestriel de son contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de Bourse Kepler Cheuvreux. Au titre du contrat de liquidit\u00e9 confi\u00e9 par la Soci\u00e9t\u00e9 MaaT Pharma \u00e0 Kepler Cheuvreux, les moyens figurant au compte de liquidit\u00e9 au 31 d\u00e9cembre 2023 \u00e9taient : 24 236 titres 34 60 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 627 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 368 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 18 328 titres pour 122 49 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 9 576 titres pour 64 03 \u20ac Il est rappel\u00e9 : que lors du dernier bilan du 30 juin 2023, les moyens suivants figuraient au compte de liquidit\u00e9 : 15 484 titres 41 13 \u20ac en esp\u00e8ces Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 l&rsquo;achat : 552 Nombre de transactions ex\u00e9cut\u00e9es sur le semestre \u00e0 la vente : 431 Volume \u00e9chang\u00e9 sur le semestre \u00e0 l&rsquo;achat : 15 974 titres pour 144 75 \u20ac Volume \u00e9chang\u00e9 sur le semestre \u00e0 la vente : 12 997 titres pour 122 16 \u20ac &nbsp; que lors de la mise en place du contrat, les moyens suivants figuraient au compte de liquidit\u00e9 : 0 titres 200 00 \u20ac en esp\u00e8ces Le contrat de liquidit\u00e9 est mis en \u0153uvre depuis le 14 mars 2022, en vertu de l&rsquo;autorisation accord\u00e9e par l&rsquo;Assembl\u00e9e G\u00e9n\u00e9rale du 3 mars 2022, renouvel\u00e9e le 19 juin 2023. La mise en \u0153uvre du pr\u00e9sent bilan est r\u00e9alis\u00e9e conform\u00e9ment \u00e0 la d\u00e9cision AMF n\u00b02021-01 du 22 juin 2021 renouvelant l\u2019instauration des contrats de liquidit\u00e9 sur titres de capital au titre de pratique de march\u00e9 admise. Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 627 18 328 122 340,49 368 9 576 64 693,03 03\/07\/2023 5 447 3 111,12 &#8211; &#8211; &#8211; 04\/07\/2023 21 845 5 391,10 &#8211; &#8211; &#8211; 05\/07\/2023 4 284 1 848,84 1 1 6,90 06\/07\/2023 4 111 747,03 1 1 6,84 07\/07\/2023 3 70 466,20 &#8211; &#8211; &#8211; 10\/07\/2023 &#8211; &#8211; &#8211; 1 50 335,00 12\/07\/2023 1 30 201,00 &#8211; &#8211; &#8211; 13\/07\/2023 3 20 133,00 &#8211; &#8211; &#8211; 14\/07\/2023 1 1 6,62 1 1 6,62 17\/07\/2023 3 110 715,00 &#8211; &#8211; &#8211; 18\/07\/2023 3 100 640,00 &#8211; &#8211; &#8211; 19\/07\/2023 1 20 128,00 2 40 258,40 20\/07\/2023 1 40 256,00 1 50 323,00 21\/07\/2023 1 40 256,00 &#8211; &#8211; &#8211; 24\/07\/2023 &#8211; &#8211; &#8211; 1 30 192,60 25\/07\/2023 2 21 134,40 1 1 6,40 26\/07\/2023 2 51 325,38 1 1 6,38 27\/07\/2023 1 50 320,00 4 66 423,72 28\/07\/2023 3 100 633,00 2 54 345,60 31\/07\/2023 3 100 621,00 3 71 454,40 01\/08\/2023 1 50 320,00 4 129 833,34 02\/08\/2023 2 80 508,00 &#8211; &#8211; &#8211; 03\/08\/2023 &#8211; &#8211; &#8211; 3 50 320,00 04\/08\/2023 5 31 195,30 1 1 6,30 07\/08\/2023 &#8211; &#8211; &#8211; 1 20 128,00 08\/08\/2023 1 20 128,00 &#8211; &#8211; &#8211; 09\/08\/2023 2 24 152,16 &#8211; &#8211; &#8211; 10\/08\/2023 1 1 6,38 1 1 6,38 11\/08\/2023 1 1 6,38 2 7 44,80 14\/08\/2023 4 50 315,00 &#8211; &#8211; &#8211; 15\/08\/2023 1 1 6,32 2 31 198,40 16\/08\/2023 3 31 195,30 1 1 6,38 17\/08\/2023 1 10 63,00 1 20 128,00 18\/08\/2023 2 21 132,30 1 1 6,38 21\/08\/2023 &#8211; &#8211; &#8211; 2 50 320,00 22\/08\/2023 2 41 258,30 1 1 6,38 23\/08\/2023 3 30 188,70 2 60 382,20 24\/08\/2023 3 30 189,00 1 20 128,00 25\/08\/2023 6 116 709,92 5 94 579,98 28\/08\/2023 5 90 547,20 2 11 69,30 29\/08\/2023 4 31 192,20 3 48 304,32 30\/08\/2023 6 370 2 353,20 &#8211; &#8211; &#8211; 31\/08\/2023 5 109 683,43 &#8211; &#8211; &#8211; 05\/09\/2023 1 1 6,30 1 1 6,30 06\/09\/2023 1 1 6,32 1 1 6,32 07\/09\/2023 7 248 1 550,00 3 150 969,00 08\/09\/2023 5 244 1 520,12 2 151 966,40 11\/09\/2023 2 6 38,04 &#8211; &#8211; &#8211; 12\/09\/2023 7 344 2 132,80 4 100 626,00 13\/09\/2023 2 31 195,30 5 81 515,16 14\/09\/2023 1 20 126,00 1 20 128,00 Achats Ventes Nombre de transactions Nombre de titres Capitaux en EUR Nombre de transactions Nombre de titres Capitaux en EUR Total 627 18 328 122 340,49 368 9 576 64 693,03 18\/09\/2023 4 151 943,75 3 80 500,80 19\/09\/2023 5 60 369,00 2 21 130,20 20\/09\/2023 2 10 63,00 4 80 511,20 21\/09\/2023 4 100 618,00 1 50 315,00 22\/09\/2023 7 239 1 465,07 1 1 6,28 25\/09\/2023 4 110 684,20 2 50 313,00 26\/09\/2023 9 430 2 558,50 2 50 314,50 27\/09\/2023 12 791 4 445,42 5 122 744,20 28\/09\/2023 12 710 3 564,20 2 200 1 008,00 29\/09\/2023 2 50 252,00 5 300 1 554,00 02\/10\/2023 3 130 661,70 &#8211; &#8211; &#8211; 03\/10\/2023 18 540 2 624,40 11 400 2 000,00 04\/10\/2023 3 130 666,90 3 110 569,80 05\/10\/2023 3 234 1 404,00 18 588 3 580,92 06\/10\/2023 2 50 313,00 3 60 379,80 09\/10\/2023 9 190 1 155,20 &#8211; &#8211; &#8211; 10\/10\/2023 5 105 628,95 2 30 183,00 11\/10\/2023 9 167 993,65 3 49 300,37 12\/10\/2023 1 1 5,82 4 51 306,00 13\/10\/2023 6 73 427,78 2 23 140,30 16\/10\/2023 1 99 588,06 1 48 288,00 17\/10\/2023 2 11 66,00 1 1 5,98 18\/10\/2023 3 35 211,75 3 39 239,85 19\/10\/2023 6 139 849,29 3 80 498,40 20\/10\/2023 3 8 48,72 2 21 129,99 23\/10\/2023 4 67 414,73 1 20 124,00 24\/10\/2023 5 74 454,36 2 21 130,20 25\/10\/2023 2 18 111,60 1 1 6,22 26\/10\/2023 &#8211; &#8211; &#8211; 8 339 2 278,08 27\/10\/2023 5 140 974,40 4 49 348,88 30\/10\/2023 6 90 632,70 1 21 151,20 31\/10\/2023 2","og_url":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","og_site_name":"MaaT Pharma","article_published_time":"2024-01-22T17:02:51+00:00","article_modified_time":"2026-01-22T14:02:19+00:00","og_image":[{"width":2362,"height":2362,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","type":"image\/png"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux","datePublished":"2024-01-22T17:02:51+00:00","dateModified":"2026-01-22T14:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"},"wordCount":762,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","url":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/","name":"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux - MaaT Pharma","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","datePublished":"2024-01-22T17:02:51+00:00","dateModified":"2026-01-22T14:02:19+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/12\/Website_maat_logo.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/january-22-2024-maat-pharma-half-year-report-on-liquidity-contract-with-the-brokerage-firm-kepler-cheuvreux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"22 janvier 2024 : MaaT Pharma : Bilan semestriel du contrat de liquidit\u00e9 contract\u00e9 avec la soci\u00e9t\u00e9 de bourse Kepler Cheuvreux"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/11889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=11889"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/11889\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/7120"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=11889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=11889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=11889"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=11889"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=11889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}